Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
Challenges of Measuring and Assessing Cognitive Health in Diverse Populations
Challenges of Measuring and Assessing Cognitive Health in Diverse Populations
-
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease
Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. Amyloid biomarker eligibility is a requirement to confirm the diagnosis of AD and for treatment with amyloid-lowering drugs and differed among racial and ethnic groups.
-
Applying for the 2024-2025 CeASES-ADRD Pilot Award
Applications are now closed.
-
USC’s Minority Aging Research Center Secures $3.6M for Alzheimer’s Research
Researchers study the health and economics issues associated with cognitive decline and dementia, and particularly the inequitable burden of Alzheimer’s.
Categorized in -
Healthcare Utilization Before and After a Dementia Diagnosis in Medicare Advantage Versus Traditional Medicare
The increase in care use leading up to a dementia diagnosis is higher among beneficiaries in traditional Medicare than in Advantage plans and remains higher after diagnosis.
-
Estimates of Diagnosed Dementia Prevalence and Incidence Among Diverse Beneficiaries in Traditional Medicare and Medicare Advantage
The prevalence of diagnosed dementia among beneficiaries in MA was lower than in TM.
-
Blood Pressure Medication and Dementia Prevention: The Promising Link
SC Schaeffer Center researchers have turned to real-world data to probe the relationship between antihypertensive use and dementia risk in the U.S. population and among minoritized populations who are at the highest risk of dementia.
Categorized in -
Does Adding MRI and CSF-Based Biomarkers Improve Cognitive Status Classification Based on Cognitive Performance Questionnaires?
MRI and CSF biomarkers, while important for understanding dementia pathology in clinical research, were not found to substantially improve cognitive status classification based on cognitive status performance.
Categorized in -
The Agency Keeping Alzheimer’s Drugs from Patients
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.
Categorized in -
Medicare’s ‘Coverage With Evidence Development’: A Barrier to Patient Access and Innovation
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
Categorized in